Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Rein Therapeutics (RNTX) Return on Capital Employed (2017 - 2025)

Rein Therapeutics (RNTX) has disclosed Return on Capital Employed for 9 consecutive years, with 0.32% as the latest value for Q4 2025.

  • Quarterly Return on Capital Employed rose 52.0% to 0.32% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.32% through Dec 2025, up 52.0% year-over-year, with the annual reading at 0.29% for FY2025, 54.0% up from the prior year.
  • Return on Capital Employed for Q4 2025 was 0.32% at Rein Therapeutics, up from 1.22% in the prior quarter.
  • The five-year high for Return on Capital Employed was 0.19% in Q1 2024, with the low at 1.45% in Q1 2023.
  • Average Return on Capital Employed over 5 years is 0.79%, with a median of 0.77% recorded in 2022.
  • The sharpest move saw Return on Capital Employed skyrocketed 126bps in 2024, then tumbled -99bps in 2025.
  • Over 5 years, Return on Capital Employed stood at 0.56% in 2021, then crashed by -131bps to 1.3% in 2022, then surged by 77bps to 0.3% in 2023, then crashed by -184bps to 0.84% in 2024, then skyrocketed by 61bps to 0.32% in 2025.
  • According to Business Quant data, Return on Capital Employed over the past three periods came in at 0.32%, 1.22%, and 1.23% for Q4 2025, Q3 2025, and Q2 2025 respectively.